Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Dana Farber
mi
from
Boston, MA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Children's Hospital New York-Presbyterian
mi
from
New York, NY
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
New York University Medical Center
mi
from
New York, NY
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Levine Children's Hospital at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Nationwide Children's Hospital
mi
from
Columbus, OH
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Oregon Health and Science University
mi
from
Portland, OR
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
St. Jude
mi
from
Memphis, TN
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
St. Jude
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Vanderbilt Children's Hospital
mi
from
Nashville, TN
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Cook Children's Medical Center
mi
from
Ft. Worth, TX
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Cook Children's Medical Center
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Seattle Children's Hospital
mi
from
Seattle, WA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
Phase I Open-Label Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  3/25/2013
University of Kansas Medical Center, Westwood Campus
mi
from
Kansas City, KA
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
Phase I Open-Label Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 3/25/2013
University of Kansas Medical Center, Westwood Campus
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
Status: Enrolling
Updated:  4/24/2013
Clinical Research Facility
mi
from
Fort Myers, FL
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
Status: Enrolling
Updated: 4/24/2013
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Children's Hospital of Orange County
mi
from
Orange, CA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Stanford Medical Center
mi
from
Stanford, CA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Stanford Medical Center
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Children'S Hospital
mi
from
Aurora, CO
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Children'S Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
All Children's Hospital
mi
from
Saint Petersburg, FL
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
John Hopkins
mi
from
Balitmore, MD
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
John Hopkins
mi
from
Balitmore, MD
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
University of Minnesota
mi
from
Minneapolis, MI
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
University of Minnesota
mi
from
Minneapolis, MI
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
UMDNJ/Robert Wood Johnson
mi
from
New Brunswick, NJ
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
UMDNJ/Robert Wood Johnson
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Montifiore Medical Center
mi
from
Bronx, NY
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Montifiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Columbia Presbyterian Med Ctr
mi
from
New York, NY
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Oregon Health & Sciences
mi
from
Portland, OR
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Oregon Health & Sciences
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Texas Children's Hospital
mi
from
Houston, TX
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Inova Fairfax Medical Center
mi
from
Falls Church, VA
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Inova Fairfax Medical Center
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated:  5/2/2013
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
Status: Enrolling
Updated: 5/2/2013
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
Tufts Medical Center
mi
from
Boston, MA
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
University of Cincinnati
mi
from
Cincinnati, OH
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/31/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/31/2013
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
TGen Clinical Research Services at Scottsdale Healthcare
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
New York Oncology Hematology PC
mi
from
Albany, NY
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Institute for Translational Oncology Research
mi
from
Greenville, SC
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Texas Oncology - Baylor, Charles A. Sammons Center
mi
from
Dallas, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Texas Oncology - Baylor, Charles A. Sammons Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Tyler Cancer Center
mi
from
Tyler, TX
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/17/2013
Northwest Cancer Specialists
mi
from
Vancouver, WA
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/17/2013
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials